Exelixis Inc.
35.65
0.35 (0.99%)
At close: Jan 14, 2025, 3:59 PM
35.69
0.11%
After-hours Jan 14, 2025, 05:54 PM EST
undefined%
Bid 34.5
Market Cap 10.18B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 1.55
PE Ratio (ttm) 23
Forward PE n/a
Analyst Hold
Ask 37.4
Volume 1,347,034
Avg. Volume (20D) 2,318,701
Open 35.25
Previous Close 35.30
Day's Range 35.05 - 35.98
52-Week Range 20.02 - 36.97
Beta undefined

About EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 17, 2000
Employees 1,310
Stock Exchange NASDAQ
Ticker Symbol EXEL

Analyst Forecast

According to 17 analyst ratings, the average rating for EXEL stock is "Hold." The 12-month stock price forecast is $34, which is a decrease of -4.63% from the latest price.

Buy 58.82%
Hold 41.18%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Exelixis Inc. is scheduled to release its earnings on Feb 4, 2025, during market hours.
Analysts project revenue of $499.38M, reflecting a 4.11% YoY growth and earnings per share of 0.33, making a 0.00% YoY.
4 weeks ago · Source
-3.83%
Exelixis shares are trading lower after B of A Sec... Unlock content with Pro Subscription
2 months ago · Source
+12.91%
Exelixis shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance above estimates.